Comparative evaluation of long non-coding RNA-based biomarkers in the urinary sediment and urinary exosomes for non-invasive diagnosis of bladder cancer

Qiu, Tongtong; Xue, Mei; Li, Xu; Li, Fangyuan; Liu, Shanshan; Yao, Chenyu; Chen, Wei

doi:10.1039/d2mo00107a

Cited by 8 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, exosomal multiple-lncRNA assays generated a pooled AUC of 0.87, while single ones gave rise to a pooled AUC of 0.82, which demonstrated the superiority of exploiting panels of exosomal ncRNAs to get a full picture. As depicted in Table 1 , exosomal lnc-MALAT1, PCAT-1, and SPRY4-IT1 from urine [ 6 ]; exosomal lnc-UCA1-201, UCA1-203, MALAT1, and LINC00355 from urine [ 8 ]; exosomal lnc-PCAT-1, UBC1, and SNHG16 from serum [ 10 ]; exosomal lnc-MIR205HG and GAS5 from urine [ 12 ]; exosomal miR-96-5p and miR-183-5p from urine [ 15 ]; exosomal miR-93-5p and miR-516a-5p from urine [ 16 ]; and exosomal lnc-RMRP, UCA1, and MALAT1 from urine [ 18 ] all manifested satisfying diagnostic value for bladder cancer. The potential molecular mechanism about the limitation of exosomal single-ncRNA biomarker maybe that aberrant levels of single ncRNA might be related to various types of cancers [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis

Zhao,

Li,

Xue

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

Background In view of discordance consisting in different reports, a meta-analysis was conducted to comprehensively evaluate the diagnostic efficacy of exosomal noncoding RNAs (ncRNAs) in blood and urine in the detection of bladder cancer. Methods Eligible studies were acquired by systematic retrieval through PubMed, Cochrane Library, and Embase. The pooled diagnostic efficacy was appraised by reckoning the area under the summary receiver operating characteristic (SROC) curve. The latent sources of heterogeneity were probed by subgroup analyses and meta-regression. STATA 12.0, Meta-DiSc 1.4, and RevMan 5.3 were applied to carry out all statistical analyses and plots. Results A total of 46 studies from 15 articles comprising 2622 controls and 3015 bladder cancer patients were included in our meta-analysis. Exosomal ncRNAs in blood and urine represented relatively satisfactory diagnostic efficacy in detecting bladder cancer, with a pooled sensitivity of 0.75, a specificity of 0.79, and an area under the SROC curve (AUC) of 0.84. Exosomal microRNAs (miRNAs) exhibited better diagnostic value with a pooled AUC of 0.91 than that of exosomal long noncoding RNAs (lncRNAs). To some extent, the heterogeneity among studies was induced by exosomal ncRNA types (miRNA or lncRNA), exosomal ncRNA profiling (single- or multiple-ncRNA), sample size, specimen types, and ethnicity. Conclusion Exosomal ncRNAs in blood and urine may play a vital role in diagnosing bladder cancer as prospective noninvasive biomarkers; nonetheless, their clinical performance needs to be confirmed by further massive proactive researches.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis

Zhao,

Li,

Xue

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…The studies over the past 10 years share some common exosomal contents including MALAT1, PCAT-1 and PTENP1. Many studies have demonstrated that these three molecules play key roles in bladder cancer and can be used as accurate biomarker for bladder cancer [ 113 , 127 , 129 , 132 , 133 ]. The phosphatase and tensin homologue (PTEN) is an essential tumor suppressor [ 138 ].…”

Section: Discussionmentioning

confidence: 99%

“…a2M (alpha-2-macroglobulin) has been reported to be upregulated in the urine exosomes of bladder cancer patients [ 112 ]. Moreover, a three exosomal lncRNA panel (RMRP, UCA1 and MALAT1) are elevated in bladder cancer, and is correlated with the tumor stage of bladder cancer [ 113 ]. Furthermore, the exosomal proteins derived from bladder cancer urine and healthy controls are significantly different, indicating their potential as a noninvasive biomarker [ 114 ].…”

Section: Introductionmentioning

confidence: 99%

“…The AUC for exosomal miR-96-5p is 0.87, with a sensitivity of 82.4% and a specificity of 91.8% [ 126 ]. The AUC of combined RMRP, UCA1 and MALAT1 is 0.875, with the sensitivity of 80% and specificity of 81.4%, respectively [ 113 ]. The AUC of combined exosomal UCAI-201, UCAI-203, MALAT1 and LINC00355 is 0.96, with a sensitivity of 92% and a specificity of 91.7%, respectively [ 127 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exosome, the glass slipper for Cinderella of cancer—bladder cancer?

Yang,

Miao,

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Exosomes are lipid bilayer vesicles with a diameter of 40–100 nm secreted by almost all cells. They have been found play crucial regulatory roles in various diseases. With the development of exosomes engineering technology, exosome-based drug delivery has also rapidly evolved. Bladder cancer is a worldwide disease with high morbidity and recurrence but lack of funding, so it is also called Cinderella. Some explorations have demonstrated that exosomes are important in the development, prognosis, diagnosis and drug delivery of bladder cancer. With the rapid development of Mass spectrometry and next-generation sequencing, increasing numbers of differentially expressed molecules derived from exosomes have been found in bladder cancer. Exosomes and their contents are largely involved in bladder cancer progression, engineering of these exosomes with the targeted genes improves their potential for drug delivery of bladder cancer. Furthermore, exosomes and their contents are relate to many characteristics of bladder cancer. Herein, we briefly search 59 researches to explore the cargoes encapsuled in exosomes of bladder cancer patients. We also summarize the biogenesis, function, expression profiles, engineering approaches and biological mechanisms of exosomes and their contents for the diagnosis, prognosis and drug delivery for bladder cancer. We aim to make it clear whether exosomes are the glass slippers of Cinderella. Graphical Abstract

show abstract

“…70 With 80.0% sensitivity and 81.4% specificity, the urine exosomal RMRP, UCA1, and MALAT1 lncRNA panel is a potential biomarker for the diagnosis of breast cancer based on The Cancer Genome Atlas (TCGA) database or literature review. 71 With an AUC value of 0.7813, UCA1 was released into exosomes and present in the serum of patients with pancreatic cancer at a significantly higher level than healthy controls. Therefore, UCA1 may be useful as an early biomarker against cancer.…”

Section: Lncrnas As Cancer Biomarkersmentioning

confidence: 94%

Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer

Davodabadi,

Mirinejad,

Malik

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

Comparative evaluation of long non-coding RNA-based biomarkers in the urinary sediment and urinary exosomes for non-invasive diagnosis of bladder cancer

Abstract: Bladder cancer (BC) frequently causes a heavy disease burden for patients because of its easy recurrence. There is still lack of convenient and effective methods to diagnose or monitor BC...

Cited by 8 publications

References 30 publications

Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis

Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis

Exosome, the glass slipper for Cinderella of cancer—bladder cancer?

Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer

Contact Info

Product

Resources

About